EVM
BNGO icon

Eaton Vance Management’s Bionano Genomics BNGO Stock Holding History

Eaton Vance Management’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-83
Closed -$129K – 1598
2022
Q1 		$129K Hold
83
– – ﹤0.01% 1775
2021
Q4 		$150K Hold
83
– – ﹤0.01% 1663
2021
Q3 		$0 Hold
83
– – ﹤0.01% 2075
2021
Q2 		$367K Buy
+83
New +$328K ﹤0.01% 1416

Other funds holding BNGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

Eaton Vance Management's BNGO Position: Q2 2022 in Review

Eaton Vance Management sold out of Bionano Genomics (BNGO) in Q2 2022, closing a stake of 83 shares — an estimated $129K sold.

Eaton Vance Management first reported a position in BNGO in Q2 2021 and held it in 4 quarters. The position peaked at $367K in Q2 2021. 143 funds tracked by Wall St. Rank hold BNGO as of Q2 2022.

  • Eaton Vance Management reported no remaining Bionano Genomics position as of Q2 2022 after selling out during the quarter.
  • Eaton Vance Management sold 83 Bionano Genomics shares in Q2 2022, an estimated $129K.
  • Eaton Vance Management first reported a position in Bionano Genomics in Q2 2021 and held it in 4 quarters.
  • Eaton Vance Management's Bionano Genomics position peaked at $367K in Q2 2021.
  • 143 funds tracked by Wall St. Rank held Bionano Genomics as of Q2 2022.

Based on Eaton Vance Management's 13F filing for Q2 2022, filed 15 Aug 2022.